iCAD, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US44934S2068
USD
3.87
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About iCAD, Inc. stock-summary
stock-summary
iCAD, Inc.
Pharmaceuticals & Biotechnology
iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.
Company Coordinates stock-summary
Company Details
98 Spit Brook Rd Ste 100 , NASHUA NH : 03062-5737
stock-summary
Tel: 1 603 882520061 917 7491494
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (10.96%)

Foreign Institutions

Held by 15 Foreign Institutions (2.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michael Klein
Executive Chairman of the Board, Chief Executive Officer
Mr. Nathaniel Dalton
Independent Director
Dr. Rakesh Patel
Independent Director
Mr. Andrew Sassine
Independent Director
Dr. Susan Wood
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Mar 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 103 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.64

stock-summary
Return on Equity

-16.98%

stock-summary
Price to Book

3.34